As reported by EU-Startups, Berlin-based REMATIQ has raised €5.4 million in seed funding to transform how MedTech companies manage regulatory compliance. Led by Project A Ventures, with participation from Amino Collective, HelloWorld, and notable angel investors, the funding will fuel the company’s growth across Europe and the U.S., expand its engineering team, and accelerate the development of its AI-native compliance platform.
Source: rematiq.com.
REMATIQ’s mission: to turn regulation from a burden into a strategic advantage for MedTech innovators.
Founded in 2023 by David Boutellier and Florian Scherer, REMATIQ addresses a persistent pain point in the industry—manual, time-consuming compliance work that consumes up to 40% of R&D resources. The platform uses artificial intelligence to translate complex global regulations, such as MDR and FDA requirements, into actionable tasks that integrate directly into existing development and quality systems. By streamlining documentation and oversight, REMATIQ claims to cut regulatory workload by as much as 90%.
An AI-based solution like REMATIQ hits the point of highest leverage in MedTech development.
Mandy Blocher, B. Braun Group
Industry stakeholders are backing the approach. “An AI-based solution like REMATIQ hits the point of highest leverage in MedTech development,” said Mandy Blocher of B. Braun Group. Project A’s General Partner Anton Waitz echoed that sentiment, noting the company’s “deep industry expertise and strong technology vision.” As the regulatory landscape continues to grow in complexity, REMATIQ aims to empower innovators to bring life-saving technologies to market faster—without sacrificing quality or safety.
